If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
median onset of action, defined as the time of first change of
glucose infusion rate postdose, was similar between study groups and
to 2.10 hours for Abasaglar
to 1.87 hours for the US-approved version of Lantus, and
to 2.13 hours for the EU-approved version of Lantus.1
onset of action for Abasalar
with dose and among patient populations, and
expected to be shorter for patients with DM compared with healthy
Linnebjerg H, Lam ECQ, Seger ME, et al. Comparison of the
pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine
and EU- and US-approved versions of Lantus insulin glargine in
healthy subjects: three randomized euglycemic clamp studies. Diabetes
Care. 2015;38(12):2226-2233. http://dx.doi.org/10.2337/dc14-2623
Data on file, Eli Lilly and Company and/or one of its subsidiaries.